The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers.
Saturno G, Lopes F, Niculescu-Duvaz I, Niculescu-Duvaz D, Zambon A, Davies L, Johnson L, Preece N, Lee R, Viros A, Holovanchuk D, Pedersen M, McLeary R, Lorigan P, Dhomen N, Fisher C, Banerji U, Dean E, Krebs MG, Gore M, Larkin J, Marais R, Springer C.
Saturno G, et al. Among authors: gore m.
Ann Oncol. 2021 Feb;32(2):269-278. doi: 10.1016/j.annonc.2020.10.483. Epub 2020 Oct 29.
Ann Oncol. 2021.
PMID: 33130216
Free PMC article.